Gilead woos Cindy Perettie from Roche to lead Kite af­ter Christi Shaw de­parts

Gilead has found the next leader for Kite in Roche on­col­o­gy vet Cindy Perettie, putting her in charge of a cell ther­a­py unit that brought in $1.5 bil­lion in 2022.

Perettie joins Gilead as EVP of Kite al­most two months af­ter for­mer Kite CEO Christi Shaw stepped down. While Perettie spent the past few years in the di­ag­nos­tics world — first as CEO of Foun­da­tion Med­i­cine and lat­er head­ing Roche’s Mol­e­c­u­lar Lab So­lu­tions af­ter Roche bought Foun­da­tion — she al­so had a back­ground in on­col­o­gy drug de­vel­op­ment and com­mer­cial­iza­tion, be­gin­ning at Genen­tech and lat­er at Roche.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER